Overview
Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Compare the potential benefits of adjuvant toremifene with or without goserelin in premenopausal women with stage I-IIIA, hormonal receptor positive breast cancer accompanied with or without chemotherapy induced amenorrhoea.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Peking Union Medical College HospitalTreatments:
Goserelin
Toremifene
Criteria
Inclusion Criteria:- Written informed consent must be obtained and documented according to the local
regulatory requirements prior to beginning specific protocol procedures
- Age of at least 18 and at most 45 years
- Spontaneous and regular menstrual periods before study entry with FSH below 15 mlU/ml
in follicular phase
- Histologically confirmed primary breast cancer with the need for anthracycline-based
chemotherapy
- Steroid receptor (estrogen and progesterone) positive tumor (diagnosis according to
hospital standard-procedures)
- No clinical evidence of local recurrence or distant metastases. Complete staging
work-up within 3 months prior to registration. All patients must have (bilateral)
mammography or breast MRI, chest X-ray; other tests may be performed as clinically
indicated
- Karnofsky-Index >80%
- Life expectancy of at least 10 years, disregarding the diagnosis of cancer
- Adequate organ function including normal red and white blood count, platelets, serum
creatinine, bilirubin, and transaminases within normal range of the institution
- Patients underwent standard Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-T)
- Patients must be available for and compliant to treatment and follow-up. Patients
registered on this trial must be treated and followed up at the participating center.
Exclusion Criteria:
- Known hypersensitivity reaction to the investigational compounds or incorporated
substances
- Prior cytotoxic treatment for any reason
- Suspected (primary or secondary) ovarian insufficiency
- Pregnant or lactating patients. Patients of childbearing potential must have a
negative pregnancy test (urine or serum) within 14 days prior to registration and must
implement adequate non-hormonal contraceptive measures during study treatment; prior
use of hormonal contraceptives has to be discontinued before first Goserelin injection
- Other serious illness or medical condition that may interfere with the understanding
and giving of informed consent and the conduct of the study
- Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or
carcinoma in situ of the uterine cervix)
- Concurrent treatment with other experimental drugs or any other anti-cancer therapy
- Concurrent treatment with sex hormones. Prior treatment must be stopped before study
entry